Carditrophin-1 (CT-1) level and Echocardiographic changes in macrosomic neonate infants | ||||
| Minia Journal of Medical Research | ||||
| Volume 32, Issue 2, April 2021, Page 67-76 PDF (388.72 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjmr.2021.231547 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Nageh Shehata1; Moustafa Abdel Raheem1; Asmaa khorshi Sadeek2; Hanan Moustafa kamel3 | ||||
| 1Department of Pediatrics, Faculty of Medicine, Minia University, El-Minya, Egypt. | ||||
| 2Department of Pediatrics, Faculty of Medicine, Minia University, El-Minya, Egypt | ||||
| 32 Departments of Clinical Pathology, Faculty of Medicine, Minya University, El-Minya, Egypt | ||||
| Abstract | ||||
| Background: Fetal macrosomia, or otherwise large-for-gestational - age (LGA) fetus/infant, applies to birth weight (BW) between 4000 and 4500g, and BW > 90th percentile for gestational age. Cardiotrophin-1(CT-1), cardiomyocytes-produce chemokine, member of the interleukin- 6 cytokine family, which acts upon the glycoprotein (GP) 130 trans- membrane receptor, plays fundamental role in fetal heart development this is up-regulated by hypoxia and inflammation and exerts potent hypertrophic action on cardiac cells. It mediates the hyperglycemia/hyperinsulinemia-induced myocardial hypertrophy and systemic atherosclerosis, and are actively involved in cardiovascular pathology. Aim of the study: To evaluate the Cardiotrophin-1level and echocardiographic findings in the macrosomic neonate's in maternity and children hospital. Methods: It is a case control study. A total 80 neonates enrolled. They were divided into 2 groups; 40 neonates' were macrosomic, 40 neonates control were healthy. Cord blood was collected and analyzed for plasma level of cardiotrophin-1 and echo study for cases and control. The two groups were subjected to careful detailed history perinatal history, complete clinical examination, echo study, and laboratory investigations including plasma level of cardiotrophin-1, random blood sugar. Results: There was a significant difference in weight, length, body area surface of macrosomic neonates at p <0.001. CT-1 is significantly high in Macrosomic neonates p<0.001. ASD was comment defect in our study present in eighteen (56.3%) Macrosomic neonates, while the increase in IVSD was highly significant in macrosomic neonates compared to control. A subgroup analysis (in the Macrosomic group) showed increased cord blood CT-1 concentrations in Macrosomic neonates with CHD, as compared to Macrosomic neonates without CHD (p1 =0.029). Subgroup analysis (in the Macrosomic group) showed increased cord blood CT-1 concentrations in IDM median 280(pg. /mL) as compared to controls median 59(pg. /mL) p2 <0.001, CT-1 concentrations was significantly elevated in Macrosomic of IDM Median 280(pg. /mL) as compared to Macrosomic of Non-diabetic mothers p1<0.001, but still significantly high in Macrosomic neonates of Non-diabetic mothers Median was 280 (pg. /mL) versus (59) in control p3<0.001. CT-1 concentrations were similar in Macrosomic with CHD and Macrosomic without CHD neonates, and positively correlated with Infant RBS (r =0.949, r = 0.948 respectively p<0.001). CT-1 concentrations were positively correlated with body surface area and birth weight in Macrosomic with CHD (r =0.888, r =0.800 respectively) and Macrosomic without CHD neonates (r =0.917, r =0.920 respectively). Conclusion: plasma cardiotrophin-1 level is significant high in macrosomic neonates, cardiac hypertrophy and anomalies are common on macrosomic neonates. | ||||
| Keywords | ||||
| cardiotrophin-1; macrosomia; echocardiography | ||||
|
Statistics Article View: 84 PDF Download: 87 |
||||
